01 / DESIGN
What was studied?
A subgroup analysis used an existing blinded trial to examine people with HIV receiving integrase-inhibitor-based treatment.
02 / FINDINGS
What did the researchers report?
Among the reported participants, tesamorelin reduced visceral and hepatic fat measurements relative to placebo, with comparable reported adverse-event frequencies.
03 / LIMITS
How should it be interpreted?
The subgroup was small and derived from a parent study. It is not an independent replication or evidence for effects in people without HIV.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.